Purpose The process of assessing patient symptoms and functionality using patient-reported outcomes (PROs) and functional performance status (FPS) is an essential aspect of patient-centered oncology research and care. However, PRO and FPS measures are often employed separately or inconsistently combined. Thus, the purpose of this study was to conduct a systematic review of the level of association between PRO and FPS measures to determine their differential or combined utility. Methods A systematic search was conducted using five databases (1966( to February 2014 to identify studies that described an association between PRO and FPS. Studies were excluded if they were non-cancer specific, did not include adults aged 18 or older, or were review articles. Publications were selected for review by consensus among two authors, with a third author arbitrating as needed. Results A total of 18 studies met inclusion criteria. FPS was primarily assessed by clinicians using the ECOG Performance Status or Karnofsky Performance Status measures. PROs were captured using a variety of measures, with numerous domains assessed (e.g., pain, fatigue, and general health status). Concordance between PROs and FPS measures was widely variable, falling in the low to moderate range (0.09-0.72).
The process of assessing patient symptoms, quality of life (QoL), and treatment-related side effects is important in the study of cancer treatment efficacy, as well as to ensure highquality, patient-centered care in oncology settings [1] . Two primary methods are utilized to assess these effects, physician-rated functional performance status (FPS) and patient-reported outcomes (PROs).
FPS refers to a patient's ability to perform activities and functions that meet basic physical needs in the face of illness [2] . Although several FPS measures exist, the two most widely used in clinical and research settings are the Eastern Cooperative Oncology Group (ECOG PS) [3] and Karnofsky Performance Scale (KPS) [4] . The ECOG PS is used by physicians to report on severity of toxicity experienced by patients on oncology treatment trials. The ECOG measures toxicity effects on a five-point scale with 0 being Bfully active, able to carry on all pre-disease performance without restriction^and 5 indicating that the patient is deceased. Similarly, the KPS is a physician-reported indicator of a patient's ability to engage in normal daily activities, as well as dependence on medical care to function. The KPS is on a scale from 100 to 0, 100 meaning that the patient has Bno complaints; no evidence of disease^and 0 meaning the patient is deceased. Basch et al. [5] indicate that clinician reports of FPS are particularly useful as strong predictors of death and emergency room visits, although they may be less accurate in assessing patient symptoms.
PROs are considered to be the Bgold standard^for the reporting of the patient symptomatic experience and are defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation or filtration of this response by a clinician or anyone else [6] . Although PROs are often used in clinical research trials, their utility can extend to multiple settings, including determining product safety and effectiveness and promoting patientcentered care (i.e., health care that incorporates active involvement of the patient in the decision-making process) that may improve patient quality of life, communication with providers, patient satisfaction, and symptom management [7] [8] [9] . PROs come in many forms but typically assess patient symptoms, side effects, and/or quality of life concerns through a selfreport, quantitative scale and are commonly used in clinical cancer research [10] . The timing of these self-report assessments differs depending on a number of factors, including the study/trial protocol, the established psychometric properties of the measurement tools for optimally avoiding recall bias, the outcome being assessed, and the setting. For example, in their study of patient-reported chemotherapy toxicity, Judson et al. [11] found that a monthly PRO assessment was more feasible than weekly.
Although these measures are often employed separately and not consistently combined, there has been a broader movement toward patient-centered care [12] with FDA recommendations encouraging researchers to integrate patient report measures into clinical trials of medication [13] . Thus, it is important to identify the level of association between FPS and PROs as an important step to determine their differential or combined utility [12] . Identifying whether PROs systematically perform better or equal to physician-rated FPS could potentially reduce staffing burden; improve the accuracy of identifying patient symptoms, treatment side effects, concerns with treatments; and promote a patient-centered care environment. Further, the use of PROs to measure performance status is increasingly becoming an area of interest in medicine, as evidenced by the National Quality Forum's (NQF) recent recommendations to create a PRO performance measure [7] . Thus, the purpose of this study was to systematically review and thus better characterize the level of association between FPS and PROs.
Method Search strategy
A comprehensive electronic literature search for articles was conducted in the following databases: PubMed, . Related terms were also incorporated into the search strategy to ensure that all relevant papers were retrieved.
Selection strategy
Studies were deemed eligible for inclusion if they included an original characterization of the level of association between physician-rated FPS and PROs in adult (i.e., age ≥18) patients with cancer.
Screening process
Initially, titles were independently reviewed for eligibility by two co-authors. Second, each potentially eligible article was randomly assigned to a pair of co-authors for full abstract screening. Articles moved forward for full-text review if both co-authors reached concensus on eligibility. In instances of disagreement, a third co-author arbitrated the article. For the full-text review phase, the randomly assigned author teams consisted of a primary reviewer and a secondary reviewer for the purposes of verification and quality assurance. Both reviewers independently completed standardized coding forms to extract the pre-determined information from each potentially eligible article. All reviewers then met as a group and compared full-text article reviews to resolve any potential discrepancies and make final decisions regarding article inclusion. Each author searched references from the included fulltext articles to determine whether they should be also considered for inclusion. Study quality was assessed using a modified version of the Downs and Black Study Quality Checklist [14] .
Results
The initial electronic literature search yielded a total of 1259 titles. A single additional title was added through hand searching. Following the process of title screening, two of the primary authors independently reviewed each of the 508 unique article abstracts; 70 (60 full-text articles, 10 conference proceeding abstracts) were retained for the full-text review. Reasons for article exclusion during the full-text review phase included the following: non-cancer (k =1), FPS was not assessed (k=14), PROs were not assessed (k=5), and the level of association between FPS and PROs was not captured/ described (k=28). A total of 18 articles met eligibility criteria and were included in this review (Fig. 1) . All but 1 of the 18 articles possessed at least half of the relevant quality indicators from a modified version of the Downs and Black Study Quality Checklist [14] . Table 1 provides study demographics and clinical characteristics of the included studies. Patients were of mixed cancer types, including breast, colorectal, non-Hodgkins lymphoma, pancreatic, kidney, and non-small-cell lung cancer. Eleven studies reported race and six studies reported ethnicity, with the majority of patients in these studies identified as White and non-Hispanic.
Study characteristics
Over half of the studies (k=10) used ECOG PS to assess FPS [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , with four using KPS [5, [25] [26] [27] , one using a modified version of KPS known as the Palliative Performance Status (PPS; [28] ) [29] , one making use of the patient-reported National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Kidney Symptom Index (NFKSI) [30] , one using the patient-reported Performance Status Scale-Head and Neck Cancer (PSS-HNC; [31] ) [32] , and one cooperative group study that used a variety of FPS measures, including ECOG PS and KPS [33] . Basch and colleagues [5] , in addition to using KPS to assess patient FPS, administered a patient-reported version of KPS scaled from 0 to 100.
The use of PRO measures in these studies was much more variable, with only the Medical Outcomes Study Short Form-36 (SF-36; [34] ), European Quality of Life (EQ-5D; [35] ), Functional Assessment of Cancer Therapy (FACT-G [36] ), and Functional Assessment of Chronic Illness Therapy (FACIT; [37] ) instruments used in multiple studies. Other PRO measures administered included the Hospital Anxiety and Depression Scale (HADS; [38] ), the MD Anderson Symptom Assessment Inventory (MDASI; [39] ), the Brief Pain Inventory (BPI; [40, 41] ), linear analogue self assessment (LASA; [33] ), and Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29 [42] ). The SF-36 and FACT-G/FACIT assessment tools are widely used measures of global QoL, including emotional, physical, social, and functional well-being. The FACT/FACIT family of measures includes a number of disease/symptom specific modules for patients with cancer, including the FACT-Lym (lymphoma), FACT-KSI (kidney symptom), FACT-Th (thrombocytopenia), FHSI-8 (hepatobiliary symptom), and FACIT-F (fatigue). EQ-5D is a brief, commonly used instrument to characterize patient health status. The HADS and BPI are well-validated measures of anxiety and depression, and pain, respectively. MDASI is a psychometrically sound assessment of QoL and symptom impact with daily activities. LASA is a single-item measure of overall QoL that uses a 0-10 numeric rating scale. PROMIS-29 captures patient-reported physical function, anxiety, depression, fatigue, sleep disturbance, and satisfaction with social role, as well as pain intensity and interference.
Associations between FPS and PRO measures
In the majority of studies (k=14), FPS was reported as being significantly positively correlated with PRO measures. This included all three studies that utilized a patient-reported assessment of FPS [5, 21, 32] . Five studies made use of PRO measures to successfully differentiate between various levels of FPS. As part of a study that validated the MDASI in patients with prostate cancer, it was found that the overall score of this measure is sensitive to differentiating between patients with good (0) or poor (≥1) ECOG PS [20] . In the validation studies for the FACT-KSI, FACT-Th FHSI-8, and FACT-Lym, the individual domain subscores for these patient-reported measures were shown to be sensitive to differentiation between patients who were rated by physicians as having ECOG PS 0, 1, or ≥2 [17, 18, 21, 24] .
There were four instances of negative and/or weak levels of association between FPS and PRO measures. These included two studies that specifically captured patient-reported fatigue via the FACIT-F (i.e., r=0.43 [26] and r=−0.55 [16] ), as well as a study that examined the level of association between FPS and PROs in patients undergoing treatment with biological response modifiers (i.e., ECOG PS vs. patient global rating of change for emotional well-being [r range 0.11-0.24], emotional-well being [r range 0.09-0.23], and change in physical functioning and well being [r range 0.25-0.37] [23] . A multicenter study that consisted of healthy volunteers and cancer trial patients, as well as hospice patients and their caregivers (N=9295) reported a significantly negative association between FPS and overall QoL, as measured by LASA (r=−0.29, p<0.0001) [33] .
Discussion
The assessment of patient outcomes is an essential component of providing patient-centered, effective care [1] . However, there is wide variation in not only measurement tools but also how the outcomes are measured, whether through clinician report in FPS measures or PROs. Thus, the current systematic review investigated the level of association between FPS and PROs in order to determine if they similarly capture patient outcomes. The findings of this systematic review were consistent with literature on clinician versus PROs that suggests that, while there is often overlap, there is also some variation in clinician and patient reports [43, 44] . This indicates that FPS and PROs provide unique information not consistently captured by one form of assessment or another. Despite strong evidence that PROs provide valuable information about patient symptoms that may not be captured by physician assessment of FPS, they are not well-integrated into clinical practice outside of research. A reliance on clinician assessment through FPS rather than PROs may be due to potential challenges in implementing PRO programs, issues with missing data, and the need to promote standardization and electronic reporting potions [12] .
When compared to FPS measures, PROs appear to offer many potential benefits to patients, treatment teams, drug developers, regulatory bodies, and insurance payment companies [45] . Through their critical assessment of the Common Terminology Criteria for Adverse Events (CTCAE), a clinician-based system for reporting adverse events [46] [47] [48] , Bruner et al. [49] argue that the CTCAE leaves room for error because the patient symptom information must go through 
GRC Patient Global
Rating of Change many channels, including the physician, medical records, data entry, and final interpretation. Given that adverse events are usually reported by clinicians, this could contribute to underreporting or inaccurately reporting symptoms [45] . It has been suggested that receiving the information directly from the patient and using that information as the symptom measure, rather than going through the clinician, is one way to make this process more direct and potentially more accurate [49] . Basch and colleagues have proposed that one way to address this issue and more accurately inform treatment and clinical research would be to encourage medical institutions to embrace collaborative reporting, such that both clinician-and patient-reported outcomes are utilized [45] . Another potential avenue of reconciling the gap between FPS and PRO information is through the use of wearable activity tracking devices (e.g., FitBit®, Garmin®, Jawbone®, and Apple Watch®) to monitor movement-related activities (e.g., steps walked, distance ran/cycled, and flights of stairs climbed) by a patient over a given time period (e.g., daily, since last visit). There has been a recent push toward the use of such technology as an objective measure of patient physical activity and quality of life in cancer survivors [50] [51] [52] . Data collected from these devices could provide important between-visit contextual information to physicians when assigning FPS scores to patients, while allowing patients to consciously monitor their activity in real time.
The findings of this review were largely limited by the limitations of the studies themselves. In particular, we were unable to conduct a meta-analysis of the findings given effect sizes were not uniformly provided across studies. Additionally, our findings indicate that there is a lack of consistency across studies investigating both FPS and PROs in how these outcomes are measured. The administration of a standard battery of FPS and PROs would enable a better assessment of the differential utility of FPS and PROs. Lastly, a direct comparison between FPS and the various physical functioning domains of the PRO measures would have greatly assisted in better understanding the association between FPS and PROs. Unfortunately none of the included articles described such a comparison, other than to illustrate that PROs could differentiate between various levels of FPS [17, 18, 21, 24] . Future studies should explicitly quantify this relationship to assist with describing how patient-reported physical functioning and FPS are associated.
Our findings suggest that FPS and PRO may provide unique information and, when combined, may facilitate more effective care for patients. This study serves as a step toward investigating the possibility of a PRO performance measure by demonstrating the need for a measure that captures both FPS and PROs.
